CALPRO AS
Plasma and serum calprotectin immunoassay Calprotectin blood test - S100A8/A9 Heterodimer
Measurement of calprotectin in blood (plasma and serum) in the assessment of inflammation and severe infection on clinical chemistry systems
Links
Organization
- CEO
- RE
Ronald Eric Long1947
- Chairman of the board
- RE
Ronald Eric Long1947
- Years since formation
- 30 years
- since Feb 20, 1995
- Type
- Limited company
- VAT registered
- Yes
- Number of employees
- 9
Ownership
- Number of shares and share classes
- 260
- 1 share class
- Total number of shareholders
- 1
- person
Financials
- Total operating income 2024
- 33,815,508
- NOK
- Annual total result 2024
- -1,524,951
- NOK
- Total equity 2024
- 17,968,926
- NOK
Last update: Sep 13, 2025
Management
Management / administration
| Name | Role | Shares |
|---|---|---|
RE 1947 | Managing Director/CEO | - |
Board
| Name | Role | Shares |
|---|---|---|
RE 1947 | Chairman | - |
AT 1969 | Board Member | - |
| Board Member | - |
Others
| Name | Role | Shares |
|---|---|---|
| Auditor | - | |
| Accountant | - |
Last update: Aug 12, 2025
Ownership
Company shareholders
| Name | Share class | Total number of shares | Share |
|---|---|---|---|
| Ordinary shares | 260 | 100 % |
Last update: Jun 2, 2025
Financials
in NOK
Summary
| Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Total operating income | 33,815,508 | 37,961,288 | 28,800,535 | 25,522,592 |
Annual Total Result | -1,524,951 | 3,432,744 | -4,498,619 | -5,160,746 |
Total assets | 23,262,497 | 24,320,562 | 23,729,166 | 28,490,952 |
Total liabilities | 5,293,571 | 4,826,685 | 7,668,033 | 7,931,199 |
Total equity | 17,968,926 | 19,493,877 | 16,061,133 | 20,559,752 |
P&L
| Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Total operating income | 33,815,508 | 37,961,288 | 28,800,535 | 25,522,592 |
Total operating costs | 36,267,242 | 35,199,146 | 33,811,036 | 30,022,783 |
Operating result | -2,451,734 | 2,762,142 | -5,010,501 | -4,500,192 |
Financial income/costs | 951,001 | 687,376 | 455,121 | -3,387 |
Profit before tax | -1,500,733 | 3,449,518 | -4,555,380 | -4,503,578 |
Total tax & extraordinary income/cost | 24,218 | 16,774 | -56,761 | 657,168 |
Annual Total Result | -1,524,951 | 3,432,744 | -4,498,619 | -5,160,746 |
Balance overview
| Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Total fixed assets | 1,107,237 | 1,260,914 | 2,123,507 | 3,118,943 |
Total current assets | 22,155,260 | 23,059,648 | 21,605,659 | 25,372,008 |
Total assets | 23,262,497 | 24,320,562 | 23,729,166 | 28,490,952 |
Short term debt | 5,293,571 | 4,826,685 | 7,668,033 | 7,931,199 |
Long term debt | 0 | 0 | 0 | 0 |
Total liabilities | 5,293,571 | 4,826,685 | 7,668,033 | 7,931,199 |
Contributed capital | 104,000 | 104,000 | 104,000 | 104,000 |
Retained earnings | 17,864,926 | 19,389,877 | 15,957,133 | 20,455,752 |
Total equity | 17,968,926 | 19,493,877 | 16,061,133 | 20,559,752 |
Total equity and liabilities | 23,262,497 | 24,320,562 | 23,729,166 | 28,490,952 |
Classification
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises